Wolfe Research upgraded shares of Oruka Therapeutics (NASDAQ:ORKA - Free Report) to a strong-buy rating in a report published on Monday morning,Zacks.com reports.
Several other brokerages also recently commented on ORKA. Wedbush reiterated an "outperform" rating and set a $40.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. Stifel Nicolaus assumed coverage on Oruka Therapeutics in a research note on Friday, October 11th. They set a "buy" rating and a $49.00 target price for the company. Finally, HC Wainwright reiterated a "buy" rating and set a $45.00 target price on shares of Oruka Therapeutics in a research note on Friday, December 20th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Oruka Therapeutics currently has an average rating of "Buy" and an average target price of $39.86.
Read Our Latest Stock Report on Oruka Therapeutics
Oruka Therapeutics Stock Down 12.8 %
Shares of NASDAQ ORKA traded down $1.68 during midday trading on Monday, hitting $11.40. 505,847 shares of the company's stock were exchanged, compared to its average volume of 289,848. Oruka Therapeutics has a 12 month low of $10.95 and a 12 month high of $53.88. The business has a 50 day moving average of $17.53. The company has a market capitalization of $399 million, a price-to-earnings ratio of -1.82 and a beta of 0.77.
Institutional Trading of Oruka Therapeutics
Institutional investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company bought a new stake in shares of Oruka Therapeutics during the 3rd quarter valued at $1,037,000. FMR LLC bought a new stake in shares of Oruka Therapeutics during the 3rd quarter valued at $114,763,000. Great Point Partners LLC bought a new stake in shares of Oruka Therapeutics during the 3rd quarter valued at $12,614,000. Braidwell LP bought a new stake in shares of Oruka Therapeutics during the 3rd quarter valued at $12,640,000. Finally, Janus Henderson Group PLC bought a new stake in shares of Oruka Therapeutics during the 3rd quarter valued at $5,840,000. 56.44% of the stock is currently owned by institutional investors.
About Oruka Therapeutics
(
Get Free Report)
Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Featured Articles
Before you consider Oruka Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.
While Oruka Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
